Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary

Molecular Cancer Research

Volumn 13, Issue 4, 2015, Pages 795-806

  Sasano, Tomoyuki ^a   Mabuchi, Seiji ^a   Kuroda, Hiromasa ^a   Kawano, Mahiru ^a   Matsumoto, Yuri ^a   Takahashi, Ryoko ^a   Hisamatsu, Takeshi ^a   Sawada, Kenjiro ^a   Hashimoto, Kae ^a   Isobe, Aki ^a   Testa, Joseph R ^b   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PERIFOSINE; PROTEIN KINASE B; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHORYLCHOLINE; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; TISSUE MICROARRAY; ADENOCARCINOMA, CLEAR CELL; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MULTIPROTEIN COMPLEXES; OVARIAN NEOPLASMS; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928042433     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0314     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al.Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel comparedwith cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al.Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365: 2473-83.
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
5. Serov SF, Scully RE, Sobin LH. International histologic classification of tumors. In: Histologic typing of ovarian tumors, vol. 9. Geneva, Switzerland: World Health Organization; 1973.
6. Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 2012;126:481-90.
7. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
8. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
9. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992;89:9267-71.
10. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT andmTORphosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-7.
11. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002;277: 33490-500.
12. Ohta T, Ohmichi M, Hayasaka T, Mabuchi S, Saitoh M, Kawagoe J, et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006;147:1761-9.
13. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174:1597-601.
14. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, MokSC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006;101:71-5.
15. Hisamatsu T, Mabuchi S,Matsumoto Y, KawanoM, Sasano T, Takahashi R, et al. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary. Mol Cancer Ther 2013;12:1367-77.
16. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10.
17. Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, et al. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecol Oncol 2013;131:207-12.
18. Sun H, Yu T, Li J. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett 2011;310:118-28.
19. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, et al.mTORis a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009;15:5404-13.
20. Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in amanner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004;145:1302-13.
21. Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010;9:2411-22.
22. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589-93.
23. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
24. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002;93:723-8.
25. Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, Mimura K, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res 2011;17:4462-73.
26. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279:23477-85.
27. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
28. Mabuchi S, Hisamatsu T, Kimura T. Targeting mTOR signaling pathway in ovarian cancer. Curr Med Chem 2011;18:2960-8.
29. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second-or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011;29:4394-400.
30. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory highgrade epithelial ovarian cancer. Gynecol Oncol 2012;126:47-53.
31. WuR,HuTC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/ AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011;17:7359-72.
32. Engel JB, Schönhals T, Häusler S, Krockenberger M, Schmidt M, Horn E, et al. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 2011;283:603-10.